Study Completed

Angina Pectoris, Postmenopause, Hormone Replacement Therapy

Bayer Identifier:

90832

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

Not Available

EU CT Number:

Not Available

Study to evaluate the effect of 1 mg Estradiol and 2 mg Drospirenone over 6 weeks on the coronary flow reserve of postmenopausal women with angina pectoris

Trial purpose

Please see attached Study Results Summary below.

Key Participants Requirements

Sex

N/A

Age

N/A

Trial summary

Enrollment Goal

Trial Dates

June 2002 - August 2003

Phase

Phase 2

Could I Receive a placebo

N/A

Products

Angeliq (E2/DRSP, BAY86-4891)

Accepts Healthy Volunteer

N/A

Primary Outcome

Secondary Outcome

Trial design

Double-blind, randomized, placebo-controlled, single center study to determine the effect of 1 mg estradiol and 2 mg drospirenone (1 tablet daily) over 6 weeks on the coronary flow reserve of post-menopausal women with angina pectoris measured by PET and echocardiography (ECHO)

Trial Type

Interventional

Intervention Type

N/A

Trial Purpose

N/A

Allocation

N/A

Blinding

N/A

Assignment

N/A

Trial Arms

N/A

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.Click here to find results for studies related to marketed products.